ALFENTA (alfentanil hydrochloride) by Pfizer is clinical pharmacology alfenta (alfentanil hydrochloride) is an opioid analgesic with a rapid onset of action. First approved in 1986.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
ALFENTA (alfentanil hydrochloride) is a rapid-onset opioid analgesic administered by injection for intraoperative and perioperative analgesia. It provides hemodynamic stability during surgical procedures with a faster recovery profile than equipotent doses of fentanyl due to its shorter terminal elimination half-life of 90-111 minutes. The drug works as a mu-opioid receptor agonist with a three-compartment distribution model, rapidly crossing the blood-brain barrier to provide analgesia.
As a mature product approaching loss of exclusivity with low competitive pressure (30), the brand team is likely focused on defensive positioning and cost management rather than growth initiatives.
CLINICAL PHARMACOLOGY ALFENTA (alfentanil hydrochloride) is an opioid analgesic with a rapid onset of action. At doses of 8-40 mcg/kg for surgical procedures lasting up to 30 minutes, ALFENTA provides analgesic protection against hemodynamic responses to surgical stress with recovery times…
Worked on ALFENTA at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Effect of a Bolus of 10 µg/kg of Alfentanil on the Pupillary Pain Index
Working on ALFENTA in its LOE-approaching phase offers limited growth opportunities but valuable experience in mature product management, payer negotiations, and competitive defense. This role is best suited for professionals seeking expertise in cost optimization and transition planning rather than launch excitement or market expansion.